Therapy Detail

Therapy Name LAG525
Therapy Description

LAG525 is a monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
LAG525 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 LAG525 is a monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02460224 Phase Ib/II LAG525 PDR001 Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT03365791 Phase II LAG525 PDR001 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Active, not recruiting